Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the sponsor.
On 2 August 2007, orphan designation (EU/3/07/462) was granted by the European Commission to SuppreMol GmbH, Germany, for recombinant human soluble Fc-gamma receptor II b for the treatment of idiopathic thrombocytopenic purpura.
The sponsorship was transferred to Baxalta Innovations GmbH, Austria in June 2017.
Recombinant human soluble Fc-gamma receptor II b
|Disease / condition||
Treatment of idiopathic thrombocytopenic purpura
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.